Innovation in Precision Cardio-Oncology During the Coronavirus Pandemic and Into a Post-pandemic World

Frontiers in Cardiovascular Medicine

article

Sherry-Ann Brown¹  June-Wha Rhee²  Avirup Guha³  Vijay U. Rao⁴ 

[1] Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin;Stanford Cardiovascular Institute, Stanford University;Harrington Heart and Vascular Institute, Case Western Reserve University;Franciscan Health

关键词: innovation;    precision;    cardio-oncology;    artificial intelligence;    machine learning;    big data;    digital health;    telemedicine;   

DOI  :  10.3389/fcvm.2020.00145

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Almost 2 million new cancer diagnoses will be made and more than 600,000 cancer deaths will occur in 2020, the equivalent of 5,000 new cases and 1,600 deaths daily (1). Juxtaposed with these staggering numbers is the prevalence of ∼17 million cancer survivors in the United States, with a projected estimate of 26 million in 2040 (2); advances in cancer treatments have significantly improved survival across cancers. With growing numbers of survivors comes a growing number of individuals at risk for or living with higher rates of cardiovascular disease than in the general population. In fact, cardiovascular disease is a leading cause of death in cancer survivors, second only to cancer recurrence or the development of new primary cancers (3). Consequently, Cardio-Oncology has emerged as a new field of medicine to specifically address cardiovascular care of cancer patients and survivors, with a particular focus on prevention.

【 授权许可】

CC BY